N-(3-((S)-2-(((R)-tert-butylsulfinyl)amino)pent-4-en-2-yl)-4-fluorophenyl)-2,2,2-trifluoroacetamide | 1200497-14-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-((S)-2-(((R)-tert-butylsulfinyl)amino)pent-4-en-2-yl)-4-fluorophenyl)-2,2,2-trifluoroacetamide
• 英文别名: N-[3-[(2S)-2-[[(R)-tert-butylsulfinyl]amino]pent-4-en-2-yl]-4-fluorophenyl]-2,2,2-trifluoroacetamide
• CAS: 1200497-14-8
• 化学式: C₁₇H₂₂F₄N₂O₂S
• 分子量: 394.433
• InChiKey: UROCFYSCASPCCT-YHAMSUFESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  77.4
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-(3-((S)-2-(((R)-tert-butylsulfinyl)amino)pent-4-en-2-yl)-4-fluorophenyl)-2,2,2-trifluoroacetamide 在 吡啶 、 盐酸 、 甲醇 、 4-二甲氨基吡啶 、 potassium osmate(VI) dihydrate 、 水 、 sodium methylate 、 potassium carbonate 、 戴斯-马丁氧化剂 、 溶剂黄146 、 N-甲基吗啉氧化物 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 丙酮 、 乙腈 、 叔丁醇 为溶剂， 反应 41.01h， 生成 (S)-(2-(bis(2,4-dimethoxybenzyl)amino)-4-(2-fluoro-5-(2,2,2-trifluoroacetamido)phenyl)-4-methyl-4H-1,3-oxazin-6-yl)methyl methanesulfonate
  参考文献：
  名称：

  OXAZINE DERIVATIVES AND A PHARMACEUTICAL COMPOSITION FOR INHIBITING BACE1 CONTAINING THEM

  摘要：

  本发明提供了一种化合物的公式(I)：其中—X═是—CR7═或—N═，环B是取代或未取代的碳环或取代或未取代的杂环，R1是取代或未取代的烷基或类似物，R2和R2'分别独立地是氢、取代或未取代的烷基或类似物，R3和R4分别独立地是氢、卤素、取代或未取代的烷基或类似物，R5是氢、取代或未取代的烷基或类似物，每个R6独立地是卤素、羟基、取代或未取代的烷基或类似物，R7是氢、卤素、羟基、取代或未取代的烷基或类似物，p是0到3的整数，或其在药学上可接受的盐，具有抑制淀粉样蛋白β产生的作用，特别是抑制BACE1的作用，并且可用作由淀粉样蛋白β蛋白的产生、分泌和/或沉积引起的疾病的治疗或预防剂。

  公开号：

  US20140051691A1
• 作为产物：
  描述：

  1-(2-氟-5-硝基苯基)乙-1-酮 在 titanium(IV) tetraethanolate 、 铁粉 、 氯化铵 作用下， 以 四氢呋喃 、 水 、 甲苯 为溶剂， 反应 14.67h， 生成 N-(3-((S)-2-(((R)-tert-butylsulfinyl)amino)pent-4-en-2-yl)-4-fluorophenyl)-2,2,2-trifluoroacetamide
  参考文献：
  名称：

  Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain

  摘要：

  Accumulation of A beta peptides is a hallmark of Alzheimer's disease (AD) and is considered a causal factor in the pathogenesis of AD. beta-Secretase (BACE1) is a key enzyme responsible for producing A beta peptides, and thus agents that inhibit BACE1 should be beneficial for disease-modifying treatment of AD. Here we describe the discovery and optimization of novel oxazine-based BACE1 inhibitors by lowering amidine basicity with the incorporation of a double bond to improve brain penetration. Starting from a 1,3-dihydrooxazine lead 6 identified by a hit-to-lead SAR following HTS, we adopted a pKa lowering strategy to reduce the P-gp efflux and the high hERG potential leading to the discovery of 15 that produced significant A beta reduction with long duration in pharmacodynamic models and exhibited wide safety margins in cardiovascular safety models. This compound improved the brain-to-plasma ratio relative to 6 by reducing P-gp recognition, which was demonstrated by a P-gp knockout mouse model.

  DOI：

  10.1021/acs.jmedchem.8b00002

文献信息

• OXAZINE DERIVATIVES AND A PHARMACEUTICAL COMPOSITION FOR INHIBITING BACE1 CONTAINING THEM
  申请人：Masui Moriyasu

  公开号：US20140051691A1

  公开（公告）日：2014-02-20

  The present invention provides a compound of formula (I): wherein —X═ is —CR 7 ═ or —N═, ring B is a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, R 1 is substituted or unsubstituted alkyl or the like, R 2 a and R 2 b are each independently hydrogen, substituted or unsubstituted alkyl or the like, R 3 and R 4 are each independently hydrogen, halogen, substituted or unsubstituted alkyl or the like, R 5 is hydrogen, substituted or unsubstituted alkyl or the like, each R 6 is independently halogen, hydroxy, substituted or unsubstituted alkyl or the like, R 7 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl or the like, p is an integer of 0 to 3, or a pharmaceutically acceptable salt thereof which has an effect of inhibiting amyloid β production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid β proteins.

  本发明提供了一种化合物的公式(I)：其中—X═是—CR7═或—N═，环B是取代或未取代的碳环或取代或未取代的杂环，R1是取代或未取代的烷基或类似物，R2和R2'分别独立地是氢、取代或未取代的烷基或类似物，R3和R4分别独立地是氢、卤素、取代或未取代的烷基或类似物，R5是氢、取代或未取代的烷基或类似物，每个R6独立地是卤素、羟基、取代或未取代的烷基或类似物，R7是氢、卤素、羟基、取代或未取代的烷基或类似物，p是0到3的整数，或其在药学上可接受的盐，具有抑制淀粉样蛋白β产生的作用，特别是抑制BACE1的作用，并且可用作由淀粉样蛋白β蛋白的产生、分泌和/或沉积引起的疾病的治疗或预防剂。
• Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial
  作者：Yuji Koriyama、Akihiro Hori、Hisanori Ito、Shuji Yonezawa、Yoshiyasu Baba、Norihiko Tanimoto、Tatsuhiko Ueno、Shiho Yamamoto、Takahiko Yamamoto、Naoya Asada、Kenji Morimoto、Shunsuke Einaru、Katsunori Sakai、Takushi Kanazu、Akihiro Matsuda、Yoshitaka Yamaguchi、Takuya Oguma、Maarten Timmers、Luc Tritsmans、Ken-ichi Kusakabe、Akira Kato、Gaku Sakaguchi

  DOI：10.1021/acs.jmedchem.0c01917

  日期：2021.2.25

  as a centrally efficacious BACE1 inhibitor that was advanced into the EARLY Phase 2b/3 clinical trial for the treatment of preclinical AD patients. Compound 1 demonstrated robust and dose-dependent Aβ reduction and showed sufficient safety margins in preclinical models. The potential of reactive metabolite formation was evaluated in a covalent binding study to assess its irreversible binding to human

  β淀粉样肽（Aβ）的积累被认为是阿尔茨海默病（AD）的致病因素之一。天冬氨酰蛋白酶 β 位点淀粉样蛋白前体蛋白裂解酶 1 (BACE1) 是 Aβ 产生的限速蛋白酶，因此，抑制 BACE1 是治疗 AD 的一种有前途的治疗方法。从二氢 1,3-噻嗪类先导化合物 J 开始，我们发现 atabecestat 1 (JNJ-54861911) 是一种中枢有效的 BACE1 抑制剂，已进入早期 2b/3 期临床试验，用于治疗临床前 AD患者。化合物1表现出强劲且剂量依赖性的 Aβ 降低作用，并在临床前模型中显示出足够的安全裕度。在共价结合研究中评估了反应性代谢物形成的潜力，以评估其与人肝细胞的不可逆结合。不幸的是，早期试验因肝酶显着升高而终止，随后对临床结果的分析显示与剂量相关的认知恶化。
• OXAZINE DERIVATIVES
  申请人：Masui Moriyasu

  公开号：US20120245157A1

  公开（公告）日：2012-09-27

  The present invention provides, for example, a compound mentioned below as a medicament for treating or preventing the diseases induced by production, secretion or deposition of amyloid-β proteins. A compound of the formula (I): wherein R 1 , R 2a , R 2b , R 3 , R 4a , R 4b , ring A and the dashed lines are defined in the specification, its pharmaceutically acceptable salt or a solvate thereof.

  本发明提供了一种如下所述的化合物作为治疗或预防由淀粉样蛋白-β的产生、分泌或沉积引起的疾病的药物。式(I)的化合物：其中R1、R2a、R2b、R3、R4a、R4b、环A和虚线在说明书中有定义，其药用可接受的盐或其溶剂化合物。
• OXAZINE DERIVATIVE AND BACE 1 INHIBITOR CONTAINING SAME
  申请人：Shionogi & Co., Ltd.

  公开号：EP2703399A1

  公开（公告）日：2014-03-05

  The present invention provides a compound of formula (I): wherein -X= is -CR7= or -N=, ring B is a substituted or unsubstituted carbocycle or a substituted or unsubstituted heterocycle, R1 is substituted or unsubstituted alkyl or the like, R2a and R2b are each independently hydrogen, substituted or unsubstituted alkyl or the like, R3 and R4 are each independently hydrogen, halogen, substituted or unsubstituted alkyl or the like, R5 is hydrogen, substituted or unsubstituted alkyl or the like, each R6 is independently halogen, hydroxy, substituted or unsubstituted alkyl or the like, R7 is hydrogen, halogen, hydroxy, substituted or unsubstituted alkyl or the like, p is an integer of 0 to 3, or a pharmaceutically acceptable salt thereof which has an effect of inhibiting amyloid β production, especially an effect of inhibiting BACE1, and which is useful as a therapeutic or prophylactic agent for diseases induced by production, secretion and/or deposition of amyloid β proteins.

  本发明提供了一种式 (I) 的化合物： 其中 -X=是-CR7=或-N=、 环 B 是取代或未取代的碳环或取代或未取代的杂环、 R1 是取代或未取代的烷基或类似物、 R2a 和 R2b 各自独立地是氢、取代或未取代的烷基或类似物、 R3 和 R4 各自独立地为氢、卤素、取代或未取代的烷基或类似物、 R5 是氢、取代或未取代的烷基或类似物、 每个 R6 独立地是卤素、羟基、取代或未取代的烷基或类似物，R7 是氢、卤素、羟基、取代或未取代的烷基或类似物、 p 是 0 至 3 的整数、 或其药学上可接受的盐，该盐具有抑制淀粉样蛋白 β 生成的作用，尤其是抑制 BACE1 的作用，可用作治疗或预防由淀粉样蛋白 β 生成、分泌和/或沉积诱发的疾病的药物。
• SULFUR-CONTAINING HETEROCYCLIC DERIVATIVE HAVING ß-SECRETASE-INHIBITING ACTIVITY
  申请人：Shionogi & Co., Ltd.

  公开号：EP2305672B1

  公开（公告）日：2019-03-27